Rhythm Pharmaceuticals Inc. (RYTM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Rhythm Pharmaceuticals Inc. (RYTM) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How RYTM Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | 89.7% | -101.2% | -$196.5K | -$116.6M | -45% |
| FY 2024 | $130.1M | 89.7% | -204% | -$260.6K | -$113.9M | -45% |
| FY 2023 | $77.4M | 44% | -238.1% | -$184.7K | -$139.6M | -6.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RYTM)
- ✓Live walkthrough of RYTM's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RYTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +45.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RYTM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RYTM. Explore sector supply chains on /butterfly.
RYTM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Rhythm Pharmaceuticals Inc. (RYTM)?
In FY 2025 (10-K), RYTM converted $189.8M of revenue into a 89.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).